Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids
- 1 March 2001
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 31 (3) , 400-408
- https://doi.org/10.1046/j.1365-2222.2001.01022.x
Abstract
Some patients with severe asthma cannot be controlled with high doses of inhaled steroids (ICS), which may be related to ongoing environmental allergen exposure.We investigated whether 10 weeks of high altitude allergen avoidance leads to sustained benefits regarding clinical and inflammatory markers of disease control in adolescents with persistent asthma despite treatment with high dose ICS.Eighteen atopic asthmatic adolescents (12–18 yr, 500–2000 µg ICS daily) with established house dust mite allergy, participated in a parallel‐group study. Quality of life (PAQL), lung function, bronchial hyperresponsiveness (BHR) to adenosine and histamine, induced sputum and urine samples were collected repeatedly from 10 patients during a 10‐week admission period to the Swiss Alps (alt. 1560 m) and at 6 weeks after return to sea level. Results were compared with those in eight patients, studied in their home environment at sea level for a similar time period. Throughout the study, asthma medication remained unchanged in both groups.During admission to high altitude, PAQL, lung function, BHR to adenosine and histamine, and urinary levels of eosinophil protein X (U‐EPX), leukotriene E4 (U‐LTE4) and 9α11β prostaglandin F2 (U‐9α11β PGF2) improved significantly (P < 0.05), with a similar tendency for sputum eosinophils (P < 0.07). Furthermore, the changes in PAQL and BHR to adenosine and histamine were greater in the altitude than in the control group (P < 0.05). At 6 weeks after renewed allergen exposure at sea level, the improvements in PAQL (P < 0.05), BHR to adenosine (P < 0.07) and histamine (P < 0.05), as well as U‐EPX (P < 0.05) and U‐LTE4 (P < 0.05) were maintained.A short period of high altitude allergen avoidance, on top of regular treatment with ICS and long‐acting β2‐agonists, results in improvement of asthma, as assessed by clinical and inflammatory markers of disease severity. These findings indicate that short‐term, rigorous allergen avoidance can improve the long‐term control of severe asthma over and above what can be achieved even by high doses of inhaled steroids.Keywords
This publication has 29 references indexed in Scilit:
- House dust mite control measures in the management of asthma: meta-analysisBMJ, 1998
- Allergen avoidance in the treatment of asthma and atopic disordersThorax, 1998
- Sensitization to Dust Mites as a Dominant Risk Factor for Asthma among Adolescents Living in Central VirginiaAmerican Journal of Respiratory and Critical Care Medicine, 1997
- The cellular and mediator basis of asthma in relation to natural historyThe Lancet, 1997
- Exposure to house dust mite allergens and the clinical activity of asthmaJournal of Allergy and Clinical Immunology, 1996
- Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma.Thorax, 1996
- Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthmaPublished by Elsevier ,1996
- Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposureAllergy, 1995
- Effective allergen avoidance at high altitude reduces allergen-induced bronchial hyperresponsiveness.American Journal of Respiratory and Critical Care Medicine, 1994
- Altitude and house dust mitesJournal of Allergy and Clinical Immunology, 1982